Needham & Company LLC Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Key Points

• Needham cut Alnylam’s price target from $357 to $243 but maintained a “buy” rating, implying roughly 39.7% upside from the prior close. The broader analyst consensus remains “Moderate Buy,” with an average target of $355.10.
• Alnylam shares fell 25.1% to $174, near their 52-week low, amid concerns about slower U.S. sales growth for Amvuttra and Onpattro despite strong investor ownership and institutional support.
• The company reported third-quarter revenue of $1.46 billion, up 16.7% year over year, and EPS of $16.26 versus an estimate of $1.66. However, the earnings beat was substantially boosted by an approximately $1.9 billion tax benefit, making it less reflective of recurring operations.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target reduced by investment analysts at Needham & Company LLC from $357.00 to $243.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Needham & Company LLC's price target indicates a potential upside of 39.66% from the company's previous close.

A number of other analysts have also commented on ALNY. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. HC Wainwright reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Zacks Research lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, October 23rd. Cantor Fitzgerald restated a "neutral" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Finally, Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a $420.00 price target for the company in a research report on Monday, August 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $355.10.

Alnylam Pharmaceuticals Trading Down 25.1%

Shares of Alnylam Pharmaceuticals stock traded down $58.40 on Thursday, reaching $174.00. 11,798,480 shares of the company were exchanged, compared to its average volume of 1,493,059. The stock has a fifty day moving average price of $239.15 and a 200-day moving average price of $288.34. The firm has a market capitalization of $23.28 billion, a price-to-earnings ratio of 32.34 and a beta of 0.28. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a fifty-two week low of $172.31 and a fifty-two week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the prior year, the business posted $2.90 earnings per share. Alnylam Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock worth $635,296,000 after acquiring an additional 174,482 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company's stock worth $219,104,000 after purchasing an additional 50,329 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $148,128,000. Finally, Swiss National Bank increased its position in shares of Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company's stock worth $128,285,000 after purchasing an additional 28,520 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and ahead of analyst expectations. Earnings of $16.26 per share also exceeded estimates by a wide margin. Alnylam Pharmaceuticals Reports Third-Quarter Earnings Results
• Positive Sentiment: The company reaffirmed its fiscal 2026 net product-sales outlook, providing some reassurance that management continues to expect solid commercial performance. Alnylam Fiscal 2026 Outlook
• Positive Sentiment: Alnylam expanded its Phase 3 nucresiran heart-disease trial while citing a high level of conviction in the program. It also highlighted continued progress across its RNA interference pipeline. Alnylam Revenue Growth and Pipeline Update
• Neutral Sentiment: The exceptionally high EPS result was helped by an approximately $1.9 billion tax benefit, making the headline earnings beat less representative of recurring operating performance. Alnylam Third-Quarter Tax Windfall
• Negative Sentiment: Shares fell even after the earnings beat as investors reacted to slower growth in U.S. Amvuttra and Onpattro sales, raising concerns about the pace of the commercial business. Alnylam Sales Growth Concerns
• Negative Sentiment: Expanding the nucresiran trial may increase development costs and extend the timeline before investors receive definitive clinical results, despite management’s confidence in the drug. Alnylam Nucresiran Study Update
• Negative Sentiment: Stifel Nicolaus downgraded ALNY from “buy” to “hold,” reflecting a more cautious view of the shares’ near-term risk-reward profile, even though its $225 price target remains above the current level.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.